Kornimate/medical-research-clean huggingface dataset:
triamcinolone levels in cochlear perilymph, lateral canal and csf

Conditions: Vestibular Schwannoma

Summary: patients undergoing surgery of a vestibular schwannoma will be included in the study. patients will receive triamcinolone acetonide 24h before surgery. during translabyrinthine surgery cochlear perilymph, perilymph from the semicircular canal and cerebrospinal fluid will be taken and analyzed for triamcinolone content. in patients undergoing middle fossa or retrosigmoid resection only cerebrospinal fluid will be taken and analyzed for triamcinolone acetonide level.

patients between 18 and 90 years undergoing surgery of a vestibular schwannoma will be included in the study. patients will be offered an application of triamcinolone acetonide intratympanically on the day before surgery. during surgery samples will be taken to define how much triamcinolone acetonide enters into the perilymphatic fluid, the perilymph of the semicircular canals and csf. patients undergoing translabyrinthine surgery will undergoing labyrinthectomy during which samples of the semicircular canal can be taken. during translabyrinthine surgery nerve monitoring will be carried out using an intracochlear electrode. before inserting the electrode perilymph of the cochlea can be taken. immediately after opening the dura cerebrospinal fluid will be taken. patients undergoing middle fossa or retrosigmoid resection of the vestibular schwannoma will not undergo sampling of the perilymph. in these patients cerebrospinal fluid will be taken to determine triamcinolone acetonide levels.

Eligibility criteria:
inclusion criteria: * patients between 18 and 90 years undergoing a surgery of the cerebellopontine angle due to vestibular schwannoma and who are willing to participate in the study exclusion criteria: * patients younger than 18 years patients who receive cortison regularly or receive cortison i.v. or p.o. preoperatively patients with contraindications against the administration of volonâa
a study of novel smoking cessation interventions in current and former injection drug users

Conditions: Tobacco Dependence

Summary: cigarette smoking is very common in current and former injection drug users and is known to cause chronic lung diseases. quitting smoking is proven to improve the health of people addicted to cigarettes. . little information exists regarding the perceptions and characteristics of drug users regarding quitting smoking. additionally, most programs designed to help people quit smoking are not very successful. one reason these programs may not work well is because it is difficult to motivate people to quit smoking. new methods of motivating changes in behavior include small monetary payments for healthy behavior and reporting breathing tests with the concept of "lung age," which is the age of an average healthy person with similar breathing test results. for example, a health care provider can report results as "although you are 50 years old, you have the lungs for a 70 year old". in this proposal, the investigators plan to first explore the beliefs and characteristics of current and former injection drug users and how they are related to quitting smoking. the investigators then plan to study whether the use of two new methods of motivation increases the chances that this group will stop smoking.


Eligibility criteria:
inclusion criteria: * active smoker exclusion criteria: * enrollment in smoking cessation protocol * current use of nicotine replacement therapy

Keywords: smoking cessation contingency management spirometry lung age
the effect of spa and massage on babies on colic symptoms

Conditions: Infantile Colic; Infantile Spasm

Summary: although various complementary health approaches have been examined to alleviate colic symptoms, there seems to be a limited number of studies on spa and massage applications. for this reason, the study was planned to determine the effectiveness of nurses' baby spa and massage practices in reducing colic symptoms in babies.

baby spa is a physiotherapy method that stimulates the baby's motor movements through water (hydrotherapy) and performs body circulation in an integrated way to balance the mind and emotions. playing with water, the baby's muscles develop, circulation accelerates and the body becomes flexible. it also increases the intestinal motility of the baby. this allows the baby to pass gas more easily. in addition, all parts of the body of the baby floating in the water develop. because in the water, the hands and legs move freely, giving the whole body the ability to move. due to the low gravitational effect while swimming in the water, the baby's ability to control their muscles develops, which allows the baby to move more and all of their muscles to work optimally. on the other hand, when the baby is in the water, he feels that he is in an environment similar to the intrauterine environment he is used to. infant massage also used to reduce the symptoms of infantile colic, is often called stimulus touch. baby massage can be defined as a relaxed conversation between parent and baby. infant massage is also called touch therapy, which refers to a technique that combines the physical benefits of human touch with emotional benefits such as mind bonding. massage is an application that makes the baby more sensitive, develops a sense of security, enables better communication with eye contact, increases comfort, creates a deep bond between parent and baby, as well as supports the baby's physical, mental and emotional development. although various complementary health approaches have been examined to alleviate colic symptoms, there seems to be a limited number of studies on spa and massage applications. for this reason, the study was planned to determine the effectiveness of nurses' baby spa and massage practices in reducing colic symptoms in babies.

Eligibility criteria:
inclusion criteria: * the willingness of the family to participate in the research * the baby is between 40 days - 4 months * the baby was born at term * birth weight between 2500 - 4500 g * the baby's diagnosis of infantile colic by the doctor * the baby has not started any treatment for infantile colic exclusion criteria: * the presence of any congenital anomaly in the baby * the baby has a diagnosis of lactose intolerance * the baby has an acute or chronic illness * there is a wound on the baby's skin or a condition that prevents massage. * having a situation that prevents communication with the mother

Keywords: i̇nfantile colic baby spa hydrotherapy massage
lagb versus vbg: 7-year results

Conditions: Morbid Obesity; Bariatric Surgery; Vertical Banded Gastroplasty; Laparoscopic Adjustable Gastric Banding; Long Term Results

Summary: the study aims to investigate the long term results of a randomized clinical single-centre trial comparing two standard operative techniques in bariatric surgery; laparoscopic adjustable gastric banding and vertical banded gastroplasty.

one hundred morbidly obese patients were included in the study. randomization between the two operative techniques was performed using a computer model. fifty patients were included in both groups. weight loss, obesity-related comorbidity, long term complications, re-operations and conversions were all prospectively investigated for a mean period of 84 months.

Eligibility criteria:
inclusion criteria: * bmi of \> 40 kg/m2 or \> 35 kg/m2 with obesity-related comorbidities * failure to achieve sustainable weight loss with proven conservative measures exclusion criteria: * severe psychiatric and / or eating disorders * unable to keep to a prescribed postoperative diet * \ 60 years * not eligible to bariatric surgery according to a member of the multidisciplinary team (psychologist, dietician, nurse practitioner, general practitioner and surgeon)

Keywords: vbg lagb long term results weight loss complications reoperations conversion
efficacay of chloroquine or hydroxychloroquine in covid-19 treatment

Conditions: COVID-19; Coronavirus Infection

Summary: chloroquine or hydroxychloroquine in covid-19 treatment

clinical study evaluating the efficacy of chloroquine or hydroxychloroquine in covid-19 treatment

Eligibility criteria:
inclusion criteria: * covid 19 patients exclusion criteria: * allergy or contraindication to the drug * pregnant or lactating * patients with cardiac problems
the preventative and therapeutical effect of ursodeoxycholic acid(udca) to short bowel syndrome patients

Conditions: Short Bowel Syndrome

Summary: the efficacy of udca in treating the parenteral nutrition-associated cholestasis(pnac) has been identified by some studies in children without short bowel syndrome(sbs).most of the adults who suffering pnac have sbs. it limits the potential function of udca because of the lack of sbs patients and malabsorption of udca.therefore, we design this clinical trial in our center of sbs to approach the preventative and therapeutical effect of udca to pnac in adults with short bowel syndrome.


Eligibility criteria:
inclusion criteria: * patients with short bowel syndrome supported by total parenteral nutrition. * patients have intestine more than 50cm. * requirements of informed consent and assent of participant, parent or legal guardian as applicable * consciousness and ability to cooperate. exclusion criteria: * patients have obstruction of biliary tract, infection, autoimmune disease, cancer * patients have intestine less than 50cm * a clinically significant laboratory abnormality or a history of significant cardiac, pulmonary, hepatic, or renal disease * female with positive pregnancy * allergy to ursodeoxycholic acid
ai assisted detection of chest x-rays

Conditions: Pulmonary Nodules, Solitary; Pulmonary Nodules, Multiple; Pulmonary Consolidation; Pneumothorax; Pneumothorax; Acute; Atelectasis; Pulmonary Calcification; Cardiomegaly; Fibrosis Lung; Pleural Effusion; Pleural Effusions, Chronic; Pneumoperitoneum

Summary: this study has been added as a sub study to the simulation training for emergency department imaging 2 study (clinicaltrials.gov id nct05427838). the lunit insight cxr is a validation study that aims to assess the utility of an artificial intelligence-based (ai) chest x-ray (cxr) interpretation tool in assisting the diagnostic accuracy, speed, and confidence of a varied group of healthcare professionals. the study will be conducted using 500 retrospectively collected inpatient and emergency department cxrs from two united kingdom (uk) hospital trusts. two fellowship trained thoracic radiologists will independently review all studies to establish the ground truth reference standard. the lunit insight cxr tool will be used to analyze each cxr, and its performance will be measured against the expert readers. the study will evaluate the utility of the algorithm in improving reader accuracy and confidence as measured by sensitivity, specificity, positive predictive value, and negative predictive value. the study will measure the performance of the algorithm against ten abnormal findings, including pulmonary nodules/mass, consolidation, pneumothorax, atelectasis, calcification, cardiomegaly, fibrosis, mediastinal widening, pleural effusion, and pneumoperitoneum. the study will involve readers from various clinical professional groups with and without the assistance of lunit insight cxr. the study will provide evidence on the impact of ai algorithms in assisting healthcare professionals such as emergency medicine and general medicine physicians who regularly review images in their daily practice.


Eligibility criteria:
inclusion criteria: * general radiologists/radiographers/physicians who review cxrs as part of their routine clinical practice exclusion criteria: * thoracic radiologists * non-radiology physicians with previous formal postgraduate cxr reporting training. * non-radiology physicians with previous career in radiology, respiratory medicine or thoracic surgery to registrar or consultant level

Keywords: radiology emergency medicine artificial intelligence chest xr x rays
the initiation of swallowing can indicate the prognosis of doc

Conditions: Minimally Conscious State; Vegetative State

Summary: this study is aimed to detect the initiation of swallowing act in doc patients, to find if it is a good item as a stimulus and to detect the relationship between the initiation of swallowing act and the prognosis of doc patients.

studies suggest that the initiation and patterning of swallowing of the pharyngeal phase is also under active cortical control for both spontaneous as well as volitional swallowing in awake humans and non-human primates. a recent study found that most patients of disorders of consciousness (doc) would recover their swallowing ability quickly. and there is no study about detecting the initiation of swallowing act in doc patients. this study is aimed to detect the initiation of swallowing act in doc patients, to find if it is a good item as a stimulus and to detect the relationship between the initiation of swallowing act and the prognosis of doc patients. doc patients were recruited (standard diagnosis procedure is 4 times crs-r testing within 2 weeks). the different four stimuli were as follows: 1) one command (as recommended in crs-r) which was "open your mouth". 2) put a spoon in front of the patient's mouth without a command. 3) one command with a spoon in front of the mouth, the command is "there is a spoon and open your mouth". 4) one command with a spoon full of water in front of the mouth, the command is "there is a spoon with water and open your mouth". we presented these stimuli orderly in front of the patient's mouth and presented any one of them over 4 trials at 15 second intervals.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * no administration of central nervous system stimulant, neuro-muscular blocking agents, or sedative within the prior 24 hours * a diagnosis of vs or mcs-, based on the behavioral assessment of standardized crs-r * periods of eye opening (indicating preserved sleep-wake cycles). exclusion criteria: * documented history of prior brain injury * premorbid illness resulting in documented functional disabilities up to time of the injury * acute illness (e.g., pyrexia, pneumonia, diarrhea) * receiving hyperbaric oxygen treatments within 2 hours * fracture of the mandible.

Keywords: disorders of consciousness swallowing prognosis prediction minimally conscious state vegetative state
a study to learn about the study medicine elranatamab alone and with daratumumab in people with multiple myeloma who have received other treatments

Conditions: Multiple Myeloma

Summary: the purpose of this clinical trial is to (1) learn whether the bcma-cd3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of elranatamab in combination with the anti-cd38 monoclonal antibody daratumumab. people with multiple myeloma who have received previous treatment including lenalidomide will be enrolled in the study. part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab. people participating in part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. part 2 will evaluate the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab. part 3 will assess the effect of increased measures to protect against infection in people treated with either elranatamab alone or together with daratumumab. all people participating in the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study.


Eligibility criteria:
inclusion criteria: * prior diagnosis of multiple myeloma as defined by imwg criteria (rajkumar et al, 2014). * measurable disease based on imwg criteria as defined by at least 1 of the following: * serum m-protein ≥0.5 g/dl. * urinary m-protein excretion ≥200 mg/24 hours. * serum immunoglobulin flc ≥10 mg/dl (≥100 mg/l) and abnormal serum immunoglobulin kappa to lambda flc ratio (\ 1.65). * prior anti-multiple myeloma therapy including treatment with lenalidomide. * ecog performance status ≤2. * resolved acute effects of any prior therapy to baseline severity or ctcae grade ≤1. * not pregnant and willing to use contraception. exclusion criteria: * smoldering multiple myeloma. * plasma cell leukemia. * amyloidosis. * poems syndrome. * stem cell transplant within 12 weeks prior to enrolment, or active graft versus host disease. * active hbv, hcv, sars-cov2, hiv, or any active, uncontrolled bacterial, fungal, or viral infection. * any other active malignancy within 3 years prior to enrolment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ. * previous treatment with a bcma-directed therapy. * live attenuated vaccine within 4 weeks of the first dose of study intervention. * administration with an investigational product (e.g. drug or vaccine) concurrent with study intervention or within 30 days preceding the first dose of study intervention used in this study.

Keywords: elranatamab pf-06863135 b-cell maturation antigen bcma bispecific antibody bcma-cd3 bispecific antibody daratumumab pomalidomide multiple myeloma relapsed multiple myeloma refractory multiple myeloma magnetismm-5
evaluating the effects of psycho-oncological education on distress and quality of life in solid tumor cancer patients

Conditions: Quality of Life

Summary: this study evaluates that effects of psycho-oncological education on distress and quality of life in solid tumor cancer patients who have completed chemotherapy with curative intent. half of the participants will received a psycho-oncological educational intervention while the other half will receive usual care.

solid tumor cancer patients who have completed chemotherapy with curative intent experience psychological distress. as a result these patients experience poorer quality of life (qol), emotional vulnerability and unnecessary emotional suffering. purpose: to determine whether the implementation of a nurse driven psycho-oncological educational session will decrease psychological distress levels and improve qol among solid tumor cancer patients who have received and completed chemotherapy with curative intent. methods: a randomized clinical trial (rct) consisting of 28 eligible patients at sibley memorial hospital will be used to compare the effect of psycho-oncological education to treatment as usual in reducing psychological distress and improving quality of life. the intervention group will receive one 60 minute session of psycho-oncological education. the comparison group will receive usual care only which includes a general information session offered prior to any treatment which addresses broad side-effects of treatment, an overview of the treatment process and identification of additional resources. participants will be assessed for psychological distress and qol levels at baseline and two weeks after the intervention.

Eligibility criteria:
inclusion criteria: * non-race specific * solid tumor cancer patient * completed chemotherapy with curative intent exclusion criteria: * diagnosis of cancer prior to cancer they are being treated for * distress score of 8 or greater * diagnosed with a psychiatric disorder * diagnosed with lymphoma or leukemia * in need of immediate crisis support

Keywords: distress
global efficacy study of mpc-7869 to treat patients with alzheimer's

Conditions: Alzheimer Disease; Dementia

Summary: this is a multinational, randomized, double blind, placebo controlled, parallel group study comparing the safety and efficacy of daily dosing of 800 mg twice daily mpc-7869 to placebo. study subjects will have the diagnosis of mild dementia of the alzheimer's type. subjects may be taking approved medication for alzheimer's disease provided the dose has been stable for at least 6 months.


Eligibility criteria:
inclusion criteria: 1. have had a diagnosis of probable alzheimer's disease 2. men or women ages greater than or equal to 55 years and living in the community at the time of enrollment (ie, not living in a rest home or nursing care facility). 3. signed the subject informed consent form (icf) and is willing and able to participate for the duration of the study. 4. ability to read and understand english, dutch, danish, flemish, french, german, italian, spanish or swedish to ensure compliance with cognitive testing and study visit procedures. 5. at least 6 years of education, or sufficient work history to exclude mental retardation. 6. female subjects must be surgically sterile or postmenopausal for \> 1 year. 7. adequate vision and hearing to participate in study assessments. 8. subjects must have a reliable caregiver who can read, understand and speak same language. exclusion criteria: 1. current evidence of other causes of dementia.. . 2. history of, or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. men with prostate cancer may be enrolled at the discretion of the sponsor. 3. use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of ad immunotherapy prior to screening. 4. major surgery and related complications not resolved within 12 weeks prior to day 1. 5. previous participation in an mpc-7869 clinical study.

Keywords: alzheimer disease dementia
treatment of mild to moderate joint pain in patients with chronic plaque psoriasis receiving efalizumab

Conditions: Arthritis; Arthralgia

Summary: the purpose of this study is to evaluate tolerability and effectiveness of conventional treatment for mild to moderate arthritic or arthralgic symptoms while subjects are being treated with efalizumab for psoriasis.

the study objective is to demonstrate that mild to moderate arthritis or arthralgia may be controlled using conventional therapy while being treated with efalizumab, without loss of efficacy.

Eligibility criteria:
inclusion criteria: * females cannot become pregnant while participating in study. * have a history of plaque psoriasis for at least 6 months. * receiving or about to receive efalizumab for the treatment of chronic plaque psoriasis. * have mild to moderate arthritis or arthralgia occurring while on treatment with efalizumab or untreated mild to moderate arthritis or arthralgia present at the time of initiating treatment with efalizumab. exclusion criteria: * previous systemic treatment with biologics other than efalizumab, within 3 months. * treatment with any systemic corticosteroids or intra-articular corticosteroid injection, cyclosporine or methotrexate within 28 days. * any previous treatment with chlorambucil or cyclophosphamide. * have active tuberculosis or are currently receiving treatment or prophylactic therapy for tuberculosis. * have other serious disorders; such as, congestive heart failure, prior or current history of blood dyscrasia, or central nervous system demyelinating disorders. * has a sensitivity, intolerance, or history of gastrointestinal bleeding associated with diclofenac, indomethacin, and/or ibuprofen.

Keywords: psoriasis, arthritis, arthralgia